The 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase/inosine monophosphate (IMP) cyclohydrolase (ATIC) catalyzes final two steps of purine nucleotide de novo biosynthetic pathway. This study reports the characterization of ATIC from Staphylococcus lugdunensis (SlugATIC). Apart from kinetic analysis and a detailed biophysical characterization of SlugATIC, the role of ATIC in cell proliferation has been demonstrated for the first time. The purified recombinant SlugATIC and its truncated domains exist mainly in dimeric form was revealed in gelfiltration and glutaraldehyde cross-linking studies. The two activities reside on separate domains was demonstrated in kinetic analysis of SlugATIC and reconstituted truncated N-terminal IMP cyclohydrolase (IMPCHase) and C-terminal AICAR transformylase (AICAR TFase) domains. Sitedirected mutagenesis showed that Lys255 and His256 are the key catalytic residues, while Asn415 substantially contributes to AICAR TFase activity in SlugATIC. The differential scanning calorimetry (DSC) analysis revealed a molten globule-like structure for independent N-terminal domain as compared with a relatively stable conformational state in full-length SlugATIC signifying the importance of covalently linked domains. Unlike reported crystal structures, the DSC studies revealed significant conformational changes on binding of leading ligand to AICAR TFase domain in SlugA-TIC. The cell proliferation activity of SlugATIC was observed where it promoted proliferation and viability of NIH 3T3 and RIN-5F cells, exhibited in vitro wound healing in NIH 3T3 fibroblast cells, and rescued RIN-5F cells from the cytotoxic effects of palmitic acid and high glucose. The results suggest that ATIC, an important drug target, can also be exploited for its cell proliferative properties.
Introduction
In de novo purine biosynthetic pathway, a bifunctional enzyme 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) encoded by purH gene catalyzes the penultimate and final steps [1] . 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (AICAR TFase; EC 2.1.2.3) catalyzes the penultimate step involving the transfer of formyl group from the cofactor, (6R)N 10 -formyl-tetrahydrofolate (10-f-THF) to the exocyclic 5-amino group of AICAR to form 
5-formyl-AICAR (FAICAR)
. Inosine monophosphate cyclohydrolase (IMPCHase; EC 3.5.4.10) catalyzes the final step in the pathway where cyclization of FAI-CAR results in loss of a water molecule to form end product of the pathway IMP. Despite the high energetic cost of de novo biosynthesis and the existence of salvage pathway, replicating cells mainly rely on the synthesis of new nucleotides, and therefore, the critical enzymes involved could be an important target for drug development [2] [3] [4] . Consequently, ATIC has been identified as the target for inhibitor design in anticancer therapy and antimicrobials against microbes [5] [6] [7] . The analysis of crystal structures of ATIC from eukaryotic and prokaryotic sources has revealed a dimeric form as functional unit [5, 8, 9] . The interface of two C-terminal domains in dimer contributes AICAR TFase active site, whereas IMPCHase active site is located in N-terminal domains of the dimer. The enzyme activity residing in N-and C-terminal domains, in dimeric form, is independent of each other as demonstrated by establishing respective enzyme activity in separately synthesized N and C domains [10] . Although crystal structures and kinetic analysis revealed a wealth of information on ATIC, a detailed biochemical and biophysical characterization of these enzymes, particularly in prokaryotes, is lacking. Another important attribute which has not been reported so far is the cell proliferation potential of ATIC enzymes. Interestingly, there had been a preliminary report by Akira et al. [11] which showed that the level of the 2.8 kb AICAR TFase/IMPCHase mRNA increased markedly at 24 h during liver regeneration. But there is no direct evidence that the liver regeneration activity was due to the ATIC protein. This report has raised our interest in studying the important aspect of cell proliferation potential of ATIC enzymes. Staphylococcus lugdunensis, a coagulase-negative staphylococci, causes various life-threatening invasive infections like catheter-related bacteremia and acute endocarditis in prosthetic and native valves. In this study, a detailed biochemical and biophysical characterization of ATIC from S. lugdunensis (SlugATIC) has been carried out. The effect of substrate binding on the structural stability and conformation of protein has also been studied. To the best of our knowledge, this is the first extensive biophysical characterization of any ATIC enzyme. The study also for the first time demonstrates the role of ATIC in cell proliferation which could have potential biotechnological applications. The structure-function insights and unraveling of cell proliferation properties in present study will further help in understanding the nature of this bifunctional enzyme and exploit its potential applications.
Results

Cloning and sequence analysis
The sequence of 492 amino acid long SlugATIC was retrieved from NCBI database with accession no. WP_012990887.1, and gene-specific primers were synthesized which resulted in amplification of 1467-bp fragment lacking the first 12 bp. Directional cloning of SlugATIC gene was done by restriction digestion and ligation into the expression vector pET-21a. The sequencing of the cloned gene verified the correct frame of insert with no mutations.
The sequence similarity search of SlugATIC amino acid sequence showed significant homology to AICAR TFase/IMP cyclohydrolase (ATIC) proteins from different sources. Further Conserved Domain Database (CDD) feature in NCBI also revealed that the protein contains two domains, an N-terminal IMP cyclohydrolase and a C-terminal AICAR TFase domain, and belongs to ATIC purH superfamily. An extra domain called as MGS (methylglyoxal synthetase) belonging to MGS-like superfamily is also found in the beginning of the protein as shown by NCBI CDD database. However, this family also includes inosine monophosphate cyclohydrolase domain, and they share a common phosphate binding site. On database searching against PDB containing known crystal structures, SlugATIC showed maximum sequence identity to ATIC enzyme from Campylobacter jejuni (39%). However, the other hits available in pdb against this sequence are not vast and contain ATIC enzyme from other sources like Thermotoga maritima, Mycobacterium tuberculosis, Homo sapiens, and Gallus gallus. These ATIC enzyme sequences shared sequence identity of 35-39% with SlugATIC sequence as revealed by BLASTp search. All of these proteins are involved in de novo purine biosynthesis pathway.
Multiple sequence alignment results revealed the conservation of the two key catalytic residues Lys255 and His256 required for AICAR TFase activity. Several other conserved residues which are essential for AICAR binding and formyl group transfer are Arg196, Tyr197, Gly285, Glu308, Ser395, Asn396, Arg416, Phe441, Asp446, Ser465, and Arg488. However Ser375 in T. maritima, another residue which has been proposed as essential for AICAR TFase activity, has been replaced by Asn415 in SlugATIC. SlugATIC resembles M. tuberculosis which also has conserved Asn446 in the place of Ser375 (T. maritima). The residues responsible for IMPCHase activity that is, Ser7, Lys11, Thr31, Thr34, Lys63, Thr64, Tyr102, Asp123, Ile124, Gly125, and Lys135 are also conserved (Fig. 1 ). These residues are mainly responsible for re-orienting the 4-carboxamide moiety conformation from the one that binds to the AICAR TFase active site to the one that promotes intramolecular cyclization to form the end product of the reaction, that is, inosine monophosphate (IMP). Interestingly, multiple sequence alignment results revealed that there is deletion of the interdomain sequence in SlugATIC. This interdomain region or the linker between the two domains is of variable length in different species of bacteria. The length of the linker is quite short in SlugATIC as compared with the length of linker in M. tuberculosis (16 amino acids) (Fig. 1) . Fig. 1 . Multiple sequence alignment of SlugATIC with other related bacterial ATIC enzymes. SlugATIC secondary structure interpreted by ESPript is shown above the alignment as coils for a-helices, arrows for b-sheets, b turns as TT letters and g as 3 10 helices. The key catalytic residues responsible for AICAR TFase activity are labeled with black triangle. Other conserved residues essential for AICAR TFase activity are shown in green boxes with Asn415 highlighted in yellow box. Blue boxes indicate the residues responsible for IMPCHase activity. The linker region is boxed for clarity, while the deleted sequence in the interdomain region is highlighted by an arrow. ATIC enzyme sequences used for alignment are Thermotoga maritima (T. maritima), Mycobacterium tuberculosis (M. tuberculosis), and Campylobacter jejuni (C. jejuni).
The presence of a comparatively short linker between the two domains is also seen in crystal structure of T. maritima. This variation in the linker region in SlugATIC sequence might cause a difference in the relative positioning of the two functional domains in comparison with the other species.
The phylogenetic analysis of related bacterial and eukaryotic ATIC enzyme sequences available in PDB database revealed that the tree can be divided into two major groups, namely group I and II. Group I represents all the bacterial ATIC enzyme sequences, while the group II comprises the eukaryotic ATIC enzyme sequence from H. sapiens and G. gallus. This division may be based on the variation caused by an extra subdomain present in the C-terminal AICAR TFase domain of eukaryotic structure [8] . As expected from sequence analysis, SlugATIC is present close to C. jejuni enzyme within group I in the phylogenetic tree (Fig. S1 ).
Overexpression and purification of SlugATIC
The overexpression of SlugATIC without His-tag was carried out in pET-21a(+) expression vector at 18°C. The recombinant SlugATIC protein was purified using a four-step procedure that employed ion exchange (both cation and anion-exchange chromatography) followed by hydrophobic interaction and gel-filtration chromatography. Initially, the supernatant was loaded onto pre-equilibrated CM-sepharose cation exchange column where the protein of interest remains unbound and came in flow through (FT). The FT containing SlugATIC was loaded onto the DEAE-sepharose column in the second step. The bound proteins were eluted using a step gradient of NaCl (0-0.5 M). The SlugATIC protein was eluted at 200 mM NaCl ionic strength. The fractions containing the protein with AICAR TFase activity were pooled, concentrated, and buffer exchanged in buffer B containing 2.5 M NaCl before loading on to the octyl sepharose 4 fast flow column. In third step, most of the SlugATIC protein bound to octyl sepharose was eluted with 1 M NaCl. The active fractions were further purified by gel-filtration column. SlugATIC was purified to homogeneity employing the above protocol and migrated as a single band with an apparent molecular mass of~54 kDa ( Fig. 2A) . The summary of the purification results is shown in Table 1 .
Localization of independent IMPCHase and AICAR TFase domains
In order to establish the independent functions residing on two domains of SlugATIC, N-and C-terminal domains were separately cloned, overexpressed, and purified. Out of three truncated versions designed, one encoded N-terminal domain , while the rest two expressed C-terminal domain with an overlapping 11 and 23 amino acid residues with N-terminal domain, respectively (Fig. 3) . All three domains were purified to homogeneity on Ni-NTA affinity chromatography, and then, His tag was cleaved off from the purified proteins (Fig. 2B-D) . The purified enzymes were assayed for AICAR TFase and IMPCHase activities and demonstrated that recombinant N-terminal domain possess only IMPCHase activity, whereas two C-terminal domains exhibited only AICAR TFase activity (Fig. 3) . Table 2 ). The maximal velocity for IMPCHase activity is higher as compared with the AICAR TFase activity, indicating the efficiency of IMPCHase enzyme activity. These results conclude that the SlugATIC is a bifunctional enzyme catalyzing both the AICAR TFase and IMPCHase activities, respectively. Further, the kinetic parameters for the Truncated N-and C-terminal domains were found to be comparable to the full-length SlugATIC (Table 2) . Like SlugATIC, the IMPCH mutant was catalytically more active than the AICAR TFase activity as per its kinetic values. Hence, it is clear that the two domains are catalytically active independently. visible precipitation was seen at lower acidic pH like 4.5. Thermostability studies showed that the enzyme was stable at lower temperatures and both the activities start declining after 45°C (Fig. 4C,D) . The optimum temperature for AICAR TFase and IMPCHase activity was determined to be 35 and 37°C (Fig. 4C,D) .
Kinetic studies
Site-directed mutagenesis
Different mutants designed by site-directed mutagenesis were evaluated for AICAR TFase activity in order to ascertain the key catalytic active site residues involved. Conserved lysine at position 255 is essential for AICAR TFase activity as its replacement by alanine resulted in complete loss of AICAR TFase activity. In contrast, an introduction of arginine at this 255 position resulted in reduced activity by a factor of 76%. Mutation of the conserved histidine at position 256 by alanine completely abolished AICAR TFase activity (Table S1) . Thus, Lys255 and His256 residues are known to play most critical role in enzyme catalytic mechanism. Substitution of asparagine by alanine in position 415 resulted in decrease in AICAR TFase activity as compared with wild-type SlugATIC, indicating it might also play essential role in substrate binding (Table S1 ).
Characterization of oligomeric state of SlugATIC and its domains
To address the question whether ATIC exists as a monomer or in a higher oligomeric form, we analyzed the oligomeric state of SlugATIC by cross-linking as well as gel-filtration studies. Initially, the potential for oligomeric association of SlugATIC was checked by glutaraldehyde cross-linking studies. The cross-linked sample exhibited two bands of different molecular weight (~54 and~116 kDa) on SDS/PAGE (Fig. 5A) . The presence of a new protein band (d) approximately double the size of the individual monomer (m) indicates the efficient cross-linking of the two SlugATIC monomers (~54 kDa) to form a dimer (~108 kDa) at varying concentrations of glutaraldehyde. However, no dimerization was observed in the absence of glutaraldehyde. Thus, glutaraldehyde crosslinking results signifies the possibility of dimerization of SlugATIC. An attempt for further confirmation of the association between subunits of SlugATIC, protein sample was applied to the HiLoad 16/600 Superdex 200 pg gel-filtration column. Purified SlugATIC eluted as a single major peak at 69.8 mL, corresponding to 106 kDa mass which is similar to dimeric SlugATIC (Fig. 5B) . Thus, SlugATIC exists as dimer in solution as confirmed by both cross-linking and gel-filtration studies.
To examine the effect of chaotropic agents on the stability of quaternary structure, SlugATIC was incubated with 2 and 4 M NaCl. The gel-filtration elution profile showed two peaks which corresponded to the dimeric (69.5 mL) and monomeric (76 mL) state of SlugATIC (Fig. 6A,B) . The second peak became more distinct with increasing concentration of NaCl (2-4 M). Similar gel- filtration chromatograms were obtained upon incubation of protein with 2 and 4 M urea (Fig. 6C,D) . Overall, the effects were more pronounced in case of 2 and 4 M urea treatment as compared with the NaCl treatment. These results conclude that the chaotropic reagents results in the dissociation of the oligomerization and the degree of dissociation is dependent on the concentration of chaotropic agent used. Purified and untagged IMPCH and AICARTF 1 proteins were also applied individually to gel-filtration column in order to analyze their oligomeric states. IMPCH also showed a single peak with the elution volume 79 mL, corresponding to its dimeric state (~45 kDa) (Fig. 5C ). Similarly, AICARTF 1 also eluted (75 mL) as a dimeric protein (Fig. 5D ). This study revealed that both the domains can self associate independently and follow the same pattern of elution as SlugATIC, it suggests that the dimerization might play an important role in the functional activity of protein.
Thermal studies by differential scanning calorimetry
Differential scanning calorimetry (DSC) thermal analysis of SlugATIC, amino-and carboxy-terminal domains, and 1 : 1 mixture of N-and C-terminal domains was carried out. The data obtained were analyzed and fit into a non-2-state model. The evaluation of melting curve for N-terminal IMPCH domain showed three thermal transitions with melting temperatures (T m ) of 48.2, 59.6, and 55.7°C (Fig. 7A and Table 3 ). The curve was found to be much broader Tables 3 and S2 .
spanning over a range of 25-65°C. The first transition at lower temperatures is comparatively broader as compared with the sharp transitions of other two higher T m . This shape difference in the three transitions within a broader peak is also supported by the molar enthalpy (ΔH) and van't hoff enthalpy (ΔH v ) changes. The first broader lower temperature transition has a greater ΔH in comparison to ΔH v , while as the peaks becomes narrower and sharper, the ΔH v increases in comparison to ΔH (Table S2) . A dip in the melting curve around 62.5°C suggests aggregation of the sample at higher temperatures. The DSC analysis of carboxy-terminal AICARTF 1 domain showed two transitions with major sharp peak at a T m of 47.2°C and a broad minor peak at T m of 40.7°C ( Fig. 7B and Table 3 (Table S2) .
Of the three transitions recorded in DSC analysis for full-length SlugATIC, the middle peak with T m of 44.8°C was most prominent as compared with two minor peaks at 42.1 and 50.5°C ( Fig. 7C and Table 3 ). The result demonstrated that despite a lower T m as compared with individual domains (Table 3) , SlugATIC adopts largely a stable prominent conformation with a T m at 44.8°C which seems to be the merge effect of two domains. The first transition at 42.1°C seems to be closer to the first T m of C-terminal AICARTF 1 domain (40.7°C), while it is hard to assign the uppermost transition but could belong to N-terminal domain ( Fig. 7A-C) . However, the ΔH and ΔH v are almost same within each transition which further revealed that there are no intermediates or aggregates of the individual domains in full-length SlugATIC (Table S2) . Furthermore, formation of the full-length SlugATIC alters the native state of isolated IMPCH domain and results in a more stable tertiary structure in comparison to the loose molten structures. The melting transition analysis of 1 : 1 mixture of N-and C-terminal IMPCH and AICARTF 1 domains revealed the importance of covalent linkage between two domains where a reduction in three respective melting temperatures as compared to SlugATIC was observed. The reduction of approximately 3.2, 1.4, and 4.4°C was observed for three melting transitions of 38.9, 43.4, and 46.1°C, respectively (Table 3) . Also, unlike SlugATIC where one prominent peak was observed at 44.8°C, the two peaks of 43.4 and 46.1°C in equimolar mixture of N-and C-terminal domains were of almost equal intensity (Fig. 7D) . The results indicate that the merge effect as one single protein unit is more evident when there is a covalent linkage between domains.
In the above experiments, DSC thermograms were collected in the presence of phosphate buffer containing NaCl and KCl. The DSC analysis in absence of salt showed the same number of transitions; however, the thermal stability decreased in all the cases (Fig. 8A-D and Table 3 ). One noteworthy change was in relative intensity and broadness of the peaks observed in the N-terminal domain. The sharpness and intensity of first transition peak were rather lower as compared with second one with quite high intensity as compared with the transitions in presence of ions. The third peak, interestingly, was quite broad spanning from 45-70°C (Fig. 8A ). These observations certainly indicate noticeable changes in the molten globule forms of N-terminal in the absence of salt.
DSC studies were also done to study the effect of mutations (K255A, K255R, H256A, N415A) on the thermal stability of SlugATIC enzyme. The mutation of Lys255 and His256 to Ala (K255A, H256A) lowered the thermo stability of SlugATIC (Fig. 9A ,C and Table S3 ). The reason for the decrease in stability can be attributed to the disruption of the hydrogen bonding interactions involving the respective side chains. On expected lines, the mutation of Lys255 to Arg (K255R) increased the T m of SlugATIC by approximately 3°C which could be due to enhanced hydrogen bonding interactions involving the larger side chain of Arg ( Fig. 9B and Table S3 ). Interestingly, the mutation of Asn415 to Ala (N415A) showed an increase in the thermostability of SlugATIC. Furthermore, a new peak appeared resulting in four melting transitions (T m of 42.4, 47.1, 53.7 and 56.0°C) as compared with usual three melting transition observed ( Fig. 9D and Table S3 ). DSC studies done at various concentrations of N415A mutant enzyme showed the new emerging peak with an increased T m in all the experiments. The Table 3 . Melting temperature (T m ) for N-terminal IMPCH domain, C-terminal-AICARTF 1 domain, full-length SlugATIC, and a mixture of N-and C-terminal (IMCPH/AICARTF 1 ) domains as determined by DSC studies. T m1 , T m2 , and T m3 indicate the temperatures of the transitions seen in the DSC denaturation curve. gel-filtration profile of this mutant (N415A), unlike the wild-type SlugATIC or its mutants, showed an extra smaller peak in addition to the main dimeric peak which may correspond to higher oligomeric state (data not shown). These results suggest that there may be association of the hydrophobic patches in the protein resulting in some sort of aggregating or higher Table S3 .
SlugATIC were used to study the effect of ligand binding on its thermostability, and finally, 0.05 mM SlugA-TIC was used. By decreasing the SlugATIC concentration from 0.12 to 0.05 mM caused a shift of the third transition peak to a lower temperature (46.9°C) ( Fig. 10A and Table 4 ). This could be due to a concentration-dependent effect and SlugATIC protein might self associate at higher concentration leading to a higher T m (50.5°C) ( Fig. 7C and Table 3 ). The thermostability of SlugATIC decreased drastically in the presence of only 5-f-THF ( Fig. 10 and Table 4 ). A decrease in T m of first peak, which probably corresponds to the AICAR TFase domain by approximately 7-10°C, was observed. As the concentration of ligand 5-f-THF was increased, the newly emerged lower transition peak at approximately 36°C becomes more distinct ( Fig. 10B-D ). The effect of the second substrate AICAR was also examined. Four transitions at a T m of 46.0, 47.7, 53.7, and 57.4°C were observed upon the addition of 1 mM AICAR to SlugATIC ( Fig. 11A and Table 4 ). Upon increasing the AICAR concentration to 2 mM, a further shift of approximately 1°C was observed (46.7-58.8°C) ( Fig. 11B and Table 4 ). It was noticed that AICAR stabilizes the protein by inducing a shift of the first two transition peaks toward higher temperature as compared with SlugATIC apo protein (Fig. 10A ). On addition of 1 mM/2 mM AICAR, there is an approximate shift of 5.6-7.1°C for the first peak and 9-10.7°C for the second peak of SlugATIC (Table 4) .
However, the third transition peak at a T m of 46.9°C is almost same in all the cases. In addition, a new peak emerges at higher end of the melting curve on addition of 1 mM/2 mM AICAR with a T m of 57.4°C/58.8°C, respectively (Fig. 11A,B) . Further, the addition of both the ligands showed increase in thermostability of SlugA-TIC (Fig. 11C,D and Table 4 ). The T m of the melting transition peaks shifted toward higher temperatures Table 4 . compensating for destabilizing effect of 5-f-THF (Fig. 11C,D and Table 4 ). An increase in the concentration of AICAR (2 mM) further enhances the thermal stability of the protein as evident from the shifting of both the first and second transition peaks toward higher end ( Fig. 11D and Table 4 ). Since, the changes involved after ligand binding are seen mainly in the first two transition peaks of SlugA-TIC, further attempts were made to directly investigate the changes involved in the C-terminal domain upon addition of both the ligands individually and in combination ( Fig. 12 and Table S4 ). The three melting transitions were observed in comparison to the AICARTF 1 apo protein. When 5-f-THF was added, a new peak appears in the beginning of the thermogram (Fig. 12A,  B ), while addition of AICAR results in the appearance of a new peak at the end of the thermogram (Fig. 12C ). Similar to SlugATIC folate DSC thermogram, here also the newly emerged peak becomes sharper and distinct with increasing 5-f-THF concentration. The addition of both the ligands together also showed three transitions at T m of 44.1, 46.7, and 51.1°C, respectively ( Fig. 12D and Table S4 ). The final transition, that is, the third newly emerged peak is again at a 1°C lower temperature as compared with the AICARTF 1 scan with AICAR alone (Fig. 12C and Table S4 ). These results again suggest that 5-f-THF results in the decreased thermal stability, while AICAR increases the stability of the protein at higher temperatures and compensates the effect of 5-f-THF on the protein.
SlugATIC accelerates wound healing of NIH 3T3 fibroblasts by inducing proliferation and migration
Wound-healing process requires a number of events to reorganize the integrity of the injured tissue. Various events are inflammation, stimulation of cell proliferation, and remodeling. In this study, cell proliferative assay and DAPI (4 0 ,6-diamidino-2-phenylindole dihydrochloride) staining were used to investigate the proliferation effect of SlugATIC on NIH 3T3 fibroblast cells (Fig. 13A-C) . We have also evaluated the woundhealing potential of SlugATIC by in vitro woundhealing assay (Fig. 13D) . We treated NIH 3T3 cells with increasing concentrations of SlugATIC for 12 and 24 h and estimated cell proliferation by MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide) assay. SlugATIC showed increase in cell proliferation in a time-and dose-dependent manner. The doses found to be significant for 12 and 24 h are 25 and 50 lM which showed 118% and 125% cell viability in 12 h, while 122% and 134% cell viability in 24 h (Fig. 13A,B) . However, at 24 h, the lower dose of SlugATIC, that is, 20 lM also showed significant cell viability (116%) of NIH 3T3 cells (Fig. 13B) . SlugA-TIC-treated NIH 3T3 cells also showed increase in DAPI fluorescence intensity as compared with the control cells which clearly revealed that SlugATIC had a role in the cell proliferation (Fig. 13C) . The rise in the DAPI fluorescence in 25 lM of SlugATIC-treated cells was due to a significant increase in the cell number. Table 4 .
Thus, DAPI staining corroborated well with MTT assay data which showed increased cell proliferation in a time-dependent manner ( Fig. 13A-C) . In lieu of the proliferation effect of SlugATIC on NIH 3T3 cells, we further performed in vitro wound-healing scratch assay in NIH 3T3 fibroblasts which mimics cell migration behavior in vivo during wound healing. The wound closure, that is, epithelialization process (involving cell migration), constitutes the most important step in wound-healing process. A wound was created by scrapping the monolayer of cells with the help of a pipette tip, and the migration of cells to fill up the wound was recorded by microscopic observations. The dose of SlugATIC (25 lM) chosen for this assay was based on proliferation activity seen by MTT assay. As shown in Fig. 13D , there was a significantly enhanced rate of wound closure in the presence of SlugATIC in a timedependent manner. The wound closure in SlugATICtreated group was~63.5% and~81.09% for 12 and 24 h, respectively, while it was~31.8% and~53.67% in untreated cells (Fig. 13D) . The promoting influence of SlugATIC on wound closure highlights its potential for wound-healing activity on NIH 3T3 fibroblasts cells.
SlugATIC protects pancreatic beta cells from palmitic acid-and high glucose-induced cytotoxicity MTT colorimetric assay was used to measure cell proliferation in RIN-5F cells, and our results clearly revealed that SlugATIC-treated cells resulted in dosedependent increase in cell proliferation in comparison with the control vehicle-treated cells. RIN-5F cells treated with 5, 10, and 15 lM of SlugATIC showed about 120%, 129%, and 135% cell viability for 48 h (P < 0.05) (Fig. 14A) . Hence, it is evident that the tested concentrations of SlugATIC do not show any toxicity to RIN-5F cells, but helps in increasing their viability and proliferation.
We next examined whether palmitic acid (PA) or high glucose (HG) effect pancreatic beta-cell viability. MTT assay exhibited that cells treated with 0.5 mM PA for 48 h showed significant reduction (~29%) in the cell viability in comparison to the untreated cells (Fig. 15A) . Similarly, the cells grown in HG medium showed considerable decrease in cell viability (~22%; Fig. 15B ). However, cells cultured in medium containing glucose (5.5 mM) showed no reduction in cell viability (Fig. 15B) . These data suggested that PA induced lipotoxicity and HG induced glucotoxicity in RIN-5F cells. Further an effort was made to examine whether SlugATIC had any protective effect on PAor HG-cultured RIN-5F cells.
Exposure of PA-treated RIN-5F cells to SlugATIC resulted in increase in the cell viability as compared with the PA-treated control cells. As shown in Fig. 14B , in PA-treated control group, the cell viability was reduced to 71% for 48 h, while SlugATIC significantly protects cell from PA-induced lipotoxicity in a dose-dependent manner. At 5, 10, and 15 lM concentrations of Table S4 .
SlugATIC, the percentage cell viability was found to be about 90, 92, and 93.5%, respectively, which was significantly more than only PA-treated group (Fig. 14B) . Similarly, SlugATIC improved the cell survival in a dose-dependent manner in case of cells grown in HG medium (25 mM glucose) as compared with the control cells incubated with same medium. The only HGincubated control cells showed the reduced cell viability (~79%; Fig. 14C ). Significant increase in cell survival has been seen in cells exposed to 5, 10, and 15 lM of SlugATIC as compared with the only HGtreated group which were found to be about 103, 118, and 124%, respectively (Fig. 14C) . These results revealed that the SlugATIC had a protective effect on the RIN-5F cells against the glucotoxicity induced by HG. The results of cell survival by MTT assay were further strengthened by DAPI staining results, where a progressive increase in cells (DAPI-stained nuclei) was seen on treatment with 5 lM of SlugATIC in comparison with the untreated control cells (Fig. 14D) . However, a clear apoptotic effect of PA or HG was seen in RIN-5F cells unexposed to SlugATIC as indicated by condensed and fragmented nuclei (Fig. 14D) . Interestingly, PA-or HG-incubated cells treated with SlugA-TIC were healthier and also showed increased population in comparison to cells only treated with PA or HG as observed by DAPI staining (Fig. 14D) . Thus, our results for the first time demonstrated that SlugATIC helps in the rescuing the pancreatic beta cells from the cytotoxic effects of PA and HG.
The proliferative effect of SlugATIC on RIN-5F cells was also evaluated by measuring the migration potential of cells toward the wound area in normal standard conditions. The wound closure of SlugATICtreated group was~72.30%, while it was~48.43% for untreated cells incubated for 48 h after scratch (Fig. 14E) . Together, it could be inferred that SlugA-TIC treatment showed increase in cell proliferation and cytoprotection of clonal pancreatic beta cells.
Possible mode of action of SlugATIC-induced cell proliferation: AICAR consumption and IMP formation ATIC is a bifunctional enzyme involved in purine biosynthesis pathway, and its AICAR TFase activity catalyzes the formylation of AICAR to produce FAI-CAR, which is subsequently cyclized to IMP by IMPCHase activity of the ATIC enzyme. Thus, AICAR is consumed in the enzymatic reaction to produce the end product of the pathway, that is, IMP nucleotide. So, in order to know the possible mechanism of cell proliferation activity of protein, whether it is due to the increase in IMP or due to the decline in level of AICAR or due to the synergistic effect of both, we tested various concentrations of AICAR and IMP independently for their effect on cell viability of NIH 3T3 and RIN-5F cells for 24 and 48 h, respectively (Fig. 16) . The result showed that treatment with AICAR resulted in decrease in cell viability in a dose-dependent manner in both the cell lines. There was a significant decrease in cell viability at 500-1000 lM doses in response to AICAR in both NIH 3T3 cells and RIN-5F cells ( Fig. 16A,C ). In contrast, we found that IMP was nontoxic at all the tested concentrations and resulted in increase in cell proliferation in a dose-dependent manner in both the cell lines. A significant increase in cell viability was observed at 50-200 lM doses of IMP in both the cells (Fig. 16B,D) . Based on this MTT result, two significant doses of AICAR (500 and 1000 lM) and IMP (50 and 100 lM) were selected for further studies.
Subsequently, NIH 3T3 cells were treated with AICAR or IMP along with SlugATIC for 24 h in order to investigate whether protein could rescue the Fig. 15 . Palmitic acid-induced lipotoxicity and high glucose-induced glucotoxicity in RIN-5F cells. Effect of (A) palmitic acid and (B) high glucose-induced cell cytotoxicity in RIN-5F cells at different time intervals as determined by MTT assay. Control represents cells cultured in standard medium. Results are the mean AE SEM for three independent experiments. *Statistically significant difference over control group at P < 0.05. cells from AICAR-induced effects or could supplement IMP in proliferation activity by MTT assay (Fig. 17A,  B) . It was observed that upon exposure of the NIH 3T3 cells to 500 lM AICAR, cell viability was reduced to 85% in comparison to the untreated cells, whereas co-incubation with 25 lM SlugATIC helped in rescuing the cells from AICAR-induced cell death and the percentage cell viability increased to 97%, which was significantly more than the only AICAR-treated group (Fig. 17A) . Similarly on treatment of NIH 3T3 cells with 100 lM IMP, an increase in cell proliferation was detected with 121% cell viability as compared with the untreated cells (Fig. 17B) . On the other hand, co-treatment with 100 lM IMP and 25 lM SlugATIC resulted in 150% cell viability, which was significantly more than the only IMP-treated group (Fig. 17B) .
Similarly, RIN-5F cells treated with 5 lM SlugATIC for 48 h also showed increase in cell proliferation with 120% cell viability. It was examined that upon subjecting the RIN-5F cells to AICAR for 48 h, the viability of cells declined to 77%, whereas co-treatment with 5 lM SlugATIC helped in rescuing almost all the cells (98%) from the toxic effects of AICAR (Fig. 17E) . Further upon treating RIN-5F cells with 50 lM IMP, an increase in cell proliferation was shown with 115% cell viability, while co-incubation with 5 lM SlugATIC resulted in concerted increase in cell proliferation with 148% cell viability, which was significantly more than the only IMP-treated group (Fig. 17F) .
Although in both the cell lines, the cytoprotective effect of SlugATIC against AICAR-induced cell death was evident against both the AICAR concentrations (500 and 1000 lM), taking into account the clinical significance of the material, the lower dosage of AICAR (500 lM) was selected for further studies. Similarly, the concerted proliferative role of SlugATIC in combination with IMP was also evident against both its concentrations.
We further performed the time-dependent study on cell viability of both the cells in presence of AICAR and IMP using SlugATIC (Fig. 17C,D,G,H) . We found that SlugATIC helped in rescuing the cells in time-dependent manner in the presence of AICAR (Fig. 17C,G) . Interestingly, SlugATIC also showed time-dependent increase in cell proliferation in the presence of IMP (Fig. 17D,H) . Thus, the two observations, firstly, narrowing down of the AICAR-induced cell death and increase in the cell viability by SlugATIC and, secondly, a concerted increase in cell proliferation along with IMP illustrated that the observed increase in cell viability is due to the SlugATIC enzyme ability to consume and regulate AICAR concentration and produce IMP, that is, energy inside the cell.
We further examined the time-dependent effects of AICAR/IMP alone or in the presence of SlugATIC on wound-healing activity (Figs 18 and 19) . In NIH 3T3 cells, as shown in Fig. 18 , the wound closure in SlugA-TIC-treated group was~77.81%, while it was~48.57% in untreated cells incubated for 24 h after scratch. However, after 500 lM AICAR treatment for 24 h, the wound closure was~24.86% as compared to the untreated cells, and on co-treatment of AICAR with SlugATIC in NIH 3T3 cells, the wound closure was~42.53% as compared with untreated cells, which was significantly higher than the only AICAR-treated cells (Fig. 18) . The percentage of uncovered scratched area after cell migration and proliferation decreased significantly after co-treatment of SlugATIC with IMP. After 25 lM SlugATIC and 100 lM IMP co-treatment, almost 92% wound closure was there which was significantly higher than the only IMP-treated cells (~67.57%; Fig. 18 ). Similarly, in RIN-5F cells, as shown in Fig. 19 , the wound closure of SlugATICtreated group was~66.44% for 48 h as compared with the untreated cells (~39.09%). On the other hand, coincubation of 500 lM AICAR and 5 lM SlugATIC resulted in~48.34% wound closure as compared with the only AICAR-treated cells (~17.38%; Fig. 19 ). In addition, SlugATIC and IMP co-treated cells also showed an increase in wound closure as compared to the only IMP-treated cells (Fig. 19) . Thus, it is evident from the results that SlugATIC significantly abolishes the celldeath effect of AICAR. Interestingly, SlugATIC along with IMP also showed an increase in cell proliferation in comparison to the IMP control. Thus, these experiments further confirmed that SlugATIC manifest its cell proliferation role due to the consumption of AICAR as well as due to the production of IMP inside the cell.
Discussion
The most of the structure-function insights on bifunctional ATIC have been obtained from kinetic and crystal structure analysis reported earlier. However, a detailed biophysical characterization has not been reported to study the conformational stability. In this study, a comprehensive and detailed kinetic and structure-function analysis involving full-length SlugATIC, truncated amino-and carboxy-terminal domains and an equimolar mixture of N-and C-terminal domains was undertaken. Both AICAR TFase and IMPCHase activities reside on separate domains and were independent of each other as quite evident on kinetic analysis of full-length and their truncated versions. The results clearly showed the low affinity of the enzyme for the leading substrate 10-f-THF as compared to second substrate AICAR in AICAR TFase activity. Likewise, a high affinity was observed for FAICAR for IMPCHase activity. The K m values obtained for 10-f-THF and AICAR in SlugATIC were identical to the values reported previously for human, chicken, and yeast ATIC enzyme [10, [12] [13] [14] . The K m value reported for human ATIC for 10-fTHF and AICAR was 60.2 lM and 16.8 lM, respectively [10] . Comparable values were seen for chicken ATIC enzyme with K m value of 84 and 15.2 lM for 10-f-THF and AICAR, respectively [12] . However, the K m values determined for SlugA-TIC are similar to the K m values reported for purified yeast Ade16p isozyme (10-f-THF: 131 lM, AICAR: 26 lM) [13] . In these ATIC enzymes also, the binding affinity for AICAR is higher as compared with the 10-f-THF, which further highlights the similarities in their kinetic mechanism. Similarly, in pea seedlings also, the binding affinity for AICAR (3.1 9 10 À5 M) was higher as compared with the 10-f-THF (2.0 9 10 À4 M) substrate [15] . Also, the K m for FAICAR of 2.1 lM compares well to the human ATIC (1.4 lM) [14] . [16] . The kinetic parameters of N-and C-terminal truncated variants also showed closely similar values to full-length SlugATIC indicating that the overall enzyme activity is not affected due to separation of two domains ( Table 2 ). The comparison of the kinetic parameters of AICAR TFase activity between the truncated domains and the full-length ATIC had also been done by Rayl et al. [10] . The analysis of effect of pH on SlugATIC showed that AICAR TFase and IMPCHase activities were quite stable around neutral and alkaline pH with optimum values of 7.8 and 8.4, respectively. A sharp decline in the activity was observed at acidic pH (below pH 6.0), which might be due to the alteration of the ionization state of the active site amino acid residues at lower pH. Likewise, the optimum temperature for AICAR TFase and IMPCHase activities was found to be 35 and 37°C, respectively. These results were similar to human and pea seedling ATIC enzyme [1, 15, 17] . The site-directed mutagenesis studies showed that the conserved Lys255 and His256 play key role in catalytic mechanism of SlugATIC, wherein their mutation to alanine resulted in complete loss of AICAR TFase activity. The mutation of another residue Asn415 to alanine resulted in significant reduction in AICAR TFase activity, indicating its role in substrate binding. Earlier also from sitedirected mutagenesis studies in human ATIC, it has been shown that the mutation of these conserved lysine and histidine results in abolishment of activity without significant change in the substrate-binding affinity [1, 18] . Earlier it has been proposed from a crystal structure of eukaryotic ATIC with AICAR and sulfonyl-antifolate inhibitors that the main chain amide of Ser450 (corresponding to SlugATIC Asn415) interacts with the sulfonyl oxygen and could also act as a potential hydrogen bond acceptor to interact with the reduced N5 position of the pterin ring of THF [5] . Interestingly, this Ser450 has been found to be conserved in all the prokaryotic crystal structures as well with the exception of M. tuberculosis ATIC (Asn446). It had been reported from crystal structure studies that key histidine residue was proposed to enhance the nucleophilicity of the 5-amino group of AICAR and also act as a catalytic base to deprotonate the AICAR amino group concomitant with nucleophilic attack of the substrate formyl group on 10-f-THF. Further key lysine residue stabilizes the oxyanion transition state and shuttle protons to the N 10 of THF [19] . The nature of quaternary functional unit of SlugA-TIC was demonstrated in glutaraldehyde cross-linking and gel-filtration studies. The analysis from both the studies revealed that SlugATIC mainly exists as a dimer. The gel-filtration analysis of independent Nand C-terminal domains of SlugATIC also revealed dimeric nature. The results unambiguously indicate that the two N-terminal domains constitute IMPCHase and two C-terminal domains AICAR TFase active sites in the dimer. The crystal structure of ATIC from prokaryotic and eukaryotic ATIC enzymes also showed dimeric form (PDB code: 3ZZM, 1ZCZ, 1P4R, 1M9N) [5, 7, 9, 19] . These results demonstrate that basic functional unit for enzymatic activity is in dimeric form. Previously, contradictory results were obtained in an attempt to determine the oligomeric state of ATIC. Vergis et al. [20] reported from analytical centrifugation studies that recombinant human ATIC exists in monomer-dimer equilibrium, and this equilibrium was affected in the presence of both of its substrates, AICAR and folate. However, gel-filtration studies of recombinant human ATIC and prokaryotic Escherichia coli ATIC revealed it to be a monomer [10, 21] . Distinctly, in yeast and T. maritima ATIC, the biologically relevant species was found to be a dimer [9, 13] . The exposure of SlugATIC to chaotropic agents like NaCl and urea affected the stability of quaternary structure of SlugATIC in dimeric form. The disruption of the dimeric interface at higher concentrations of NaCl suggests that various weak-polar interactions and salt bridges exist between the two subunits to stabilize the dimer. In addition, inter-molecular hydrophobic interactions also play an important role in the stability of the SlugATIC dimer as indicated by the disruption of the dimeric interface by urea.
The DSC studies provided insights into the conformational flexibility, thermal stability, domain interactions, and the structural changes on ligand binding of the full-length SlugATIC and its truncated domains. The DSC analysis of C-terminal AICARTF domain revealed a rather stable native structure with the major sharp melting transition at T m of 47.2°C (Fig. 7B) . In contrast, a relatively broader spanning melting curve of N-terminal IMPCH domain, in DSC analysis, points to the multiple conformational states or a molten globule-like native structure. However, the T m for the three transitions at 48.2, 55.7, and 59.6°C was higher than that of C-terminal domain, indicating the thermal stability of N-terminal IMPCH domain despite a much broader spanning melting curve (Fig. 7) . The DSC analysis of full-length SlugATIC showed only three transitions with one having T m of 44.8°C being the most prominent one (Fig. 7C ). This peak certainly seems to represent the merge effect of two domains with very closely spaced conformation states. However, the other two minor transitions with T m of 42.1 and 50.5°C could represent either C-and N-terminal domains, respectively, or a combined effect of two domains. This implies that N-terminal IMPCH domain somewhat stabilizes on interaction with Cterminal domain as it attains a more stable structural fold in full-length SlugATIC as compared with a molten globule structure in free-form. Also, the lower T m of the major transition peak in case of SlugATIC as compared to individual domains could be attributed to stabilization of N-terminal domain and could have functional implications (Table 3) . Interestingly, a reduction in T m (38.9, 43.4, and 46.1°C) of melting transitions were observed on DSC analysis of an equimolar mixture of two domains with none of peaks as prominent as was case in full-length SlugATIC (Fig. 7D ). This showed that the interactions between two domains are stronger resulting in a stable quaternary structure when they are covalently linked in fulllength SlugATIC as compared to the interactions between independent domains. The covalent linked domains might be essential for attaining the right conformation required for optimum enzyme function in the dimeric form of SlugATIC. The importance is also highlighted from the fact that two independent enzyme activities has remained on single polypeptide chain through evolution in nature. Similar studies had been reported in case of human NFU protein by Li et al. [22] . They additionally reported through NMR studies that the molten globule domain adopts an alternative conformation on binding to the rigid domain, a feature required for the stability of full-length NFU protein. The conserved Lys255 and His256 plays key role in AICAR TFase activity along with Asn415, which has important role in enzyme activity as shown by site-directed mutagenesis studies. The mutation of these key residues showed significant changes in thermostability of SlugATIC in DSC analysis (Fig. 9) . A decrease in thermal stability of SlugATIC mutants (K255A and H256A) as observed in DSC analysis suggests that these residues take part in stabilizing the conformational structure of SlugATIC enzyme. However, the K255R mutation rather enhanced the thermostability, in DSC analysis, due to additional hydrogen bonding interactions between the two monomers. Surprisingly, despite the disruption of hydrogen bonding interaction, N415A mutant played an important role in enhancing the thermostability of protein as apparent from the appearance of a new calorimetric transition with increased T m underlining the stabilization induced by association of hydrophobic patches due to the replacement of Asn to Ala. However, this observation needs further structural interpretation. The effect of ionic strength was also examined as all the experiments were performed in the presence of salt. The absence of salt in the buffer reduced the T m drastically for respective transitions in all the case demonstrating the role of hydrophobic interaction at the dimer interface (Fig. 8) . The presence of ligands also affected the thermal stability of the full-length SlugA-TIC providing glimpse into the conformational changes due to the nature of substrate binding. The experiments were carried out using ligands for penultimate AICAR TFase activity. We found that 5-f-THF and AICAR have opposite effect on thermal stability of SlugATIC and its C-terminal domain (Figs 10-12 ). The addition of 5-f-THF, the leading substrate for Cterminal AICARTF domain, exhibited a decrease in thermostability of the protein as evident from the shifting of the first low temperature peak by 7-10°C in SlugATIC (Fig. 10) . On closer observation in Cterminal AICARTF 1 domain, a newly emerged transition peak at a lower T m of 34.5°C was observed which clearly implies that a new conformational state arises after interaction with folate moiety (Fig. 12A,B) . As the newly emerged transition peak becomes more distinct on increasing the concentration of 5-f-THF, it further revealed that 5-f-THF binding may need opening up of the binding pocket located at the interface of two C-terminal domains. This particular observation of significant conformational changes on binding of first substrate has not been clearly observed in previously reported ATIC enzyme crystal structure. This could be due to the unavailability of ATIC crystal structure with naturally occurring 10-f-THF (due to its unstability) with a reduced pterin flexible ring which could have more favorable interactions in the folate binding site/pocket in comparison to the available crystal structures of ATIC with the folate analogs which have rigid aromatic deazafolate ring [6, 23] . Interestingly, GAR TFase another enzyme utilizing 10-f-THF in the de novo pathway had been reported to show large conformational change in the folate binding loop (open and closed conformation) which sequesters the folate from bulk solvent [23, 24] . The isomerism of the loop occurs at different pH values and upon ligand-induced binding. GAR TFase also exhibits pH-dependent enzyme activity similar to SlugATIC, with maximum at around pH 7.5-8 and inactive at acidic pH [25] . The addition of second substrate AICAR alone resulted in increased thermostability of SlugATIC, which could be attributed to the stabilization of the native fold of the protein by specific ligand binding to the native state (Figs 11A,B and 12C) [26] . These results go in accordance with the fact that the binding site for AICAR is preformed/rigid and thus requires the protein to be folded in its native conformation [5] . However, when the second substrate AICAR is added together with 5-f-THF, the stabilizing effect of AICAR predominates and reverses the destabilization effect of first substrate 5-f-THF (Fig. 11C,D  and 12D) . Apparently, the leading or first substrate preferentially binds and stabilizes an open state with an exposed binding site followed by binding of second substrate AICAR leading to a stabilized closed state. These results are in agreement with the binding order of the substrates to the ATIC enzyme and signify the binding of folate substrate first followed by AICAR [1, 12] , as if any opening up of the dimeric interface by the formyl substrate occurs, it is stabilized by the binding of AICAR at a later step. Interestingly, in all the ligand binding experiments in SlugATIC, the third transition peak is retained at a common position of approximately 47°C, which further suggests that this peak could correspond to the N-terminal domain of SlugATIC (Table 4) . Additionally, the shifting of the first two peaks of SlugATIC along with the ligand binding studies of C-terminal domain clearly supports the previous studies that 5-f-THF and AICAR bind to the C-terminal domain of SlugATIC as changes in stability indicate ligand binding as reported previously also for various other enzymes (Tables 4 and S4 ) [27] .
To the best of our knowledge, one of the areas which have not been studied till date is the property of ATIC enzyme in promoting cell proliferation and thereby its potential therapeutic applications in areas like wound healing, protection from cell cytotoxic effects. For exploring the biomedical applications, in this study, first it was established that SlugATIC is nontoxic to the cells, and additionally, our results demonstrated that it increased their viability and proliferation (Figs 13 and 14) . Cell proliferation and migration, the two essential elements involved in tissue rehabilitation, are stimulated by SlugATIC which elucidates its ability to promote the wound healing of NIH 3T3 cells as evident from the enhanced rate of wound closure seen in SlugATIC-treated NIH 3T3 fibroblast cells. Our data showed that PA and HG induced the lipotoxicity and glucotoxicity in pancreatic beta cells (Fig. 15A,B) were also supported by Maedler et al. and Varshney et al. [28, 29] . These studies exhibited that exposure to free fatty acid or HG lead to induction of apoptosis in pancreatic beta cells. As the apoptosis of pancreatic beta cell results in decreased beta-cell mass which in turn results in decreased insulin secretion; therefore, glucotoxicity and lipotoxicity contributing to the pancreatic beta-cell apoptosis constitute two important factors that lead to the pathogenesis of type-2 diabetes. Thus, SlugATIC being a protective agent against the cytotoxicity induced by PA and HG in RIN-5F cells can be used as a therapeutic agent to prevent the development of type-2 diabetes. The reason for ATIC as a proliferative agent could be due to its role in de novo purine biosynthesis pathway leading to the formation of IMP nucleotide, which is required for DNA synthesis. Interestingly, the mode of action of this enzyme may also depend on the utilization of its substrate AICAR which is an analog of AMP. Moreover, AICAR is utilized exclusively by the ATIC enzyme in de novo purine biosynthesis pathway in the cell [30, 31] . Our results also showed increase in cell viability in AICAR/IMPtreated cells in presence of SlugATIC, which illustrated that the cell proliferative property of the SlugATIC enzyme is due to the consumption of AICAR as well as due to the production of energy, that is, IMP inside the cell (Figs 17-19) . ATIC regulates the AICAR concentration which otherwise upon accumulation acts as an activator of the cellular energy sensor adenosine monophosphate-activated protein kinase (AMPK), an important regulator of cell growth, proliferation and apoptosis [32, 33] . Previous studies by Cai et al. also showed that activation of AMPK by AICAR results in suppressed glucose-induced insulin secretion in mouse pancreatic beta cells (MIN6 cells) by increasing the superoxide formation leading to mitochondrial dysfunction and apoptosis [34] . Moreover, the activation of AMPK by AICAR inhibits the cell proliferation and helps in the cell cycle arrest in many cancer cell lines [35, 36] . AICAR can also inhibit proliferation and induce apoptosis by downregulating the cell cyclins, AKT/mTOR pathway, and upregulating the p53/ERK pathway [36, 37] . This highlights the importance of ATIC inhibitors for use in cancer therapy, as has also been reported by Spurr et al. on a breast cancer cell line [38] . In addition, it was recently reported that Pemetrexed, a widely used drug for the first-line therapy of mesothelioma and non-small-cell lung cancer, inhibits de novo purine biosynthesis by inhibiting ATIC enzyme, leading to accumulation of AICAR and activation of AMPK and subsequent inhibition of mTOR pathway [39] . Similarly, the use of an ATIC homodimerization inhibitor also targeted AMPK and its downstream signaling pathway [31] . However, efficient utilization of the substrate AICAR by ATIC might have positive effects in terms of no activation of AMPK and hence allowing the cell to proliferate and might help in various cytotoxic or wound conditions (Fig. 20) . The cross talk of ATIC and AMPK needs to be warranted further by additional experiments to decipher the precise mode of action of ATIC enzymes as proliferative molecule and support its use as a therapeutic agent. This study represents the initial step in exploring the biotechnological applications of SlugA-TIC enzyme, while there is still much more to be focused for further studies, like the in vivo woundhealing activity assays, SlugATIC incorporated into a nanoparticle as an effective strategy for fastening wound-healing process, or various other applications such as use for anti-wrinkle cream, etc.
Materials and methods
Sequence analysis
Amino acid sequence of SlugATIC retrieved from NCBI was used as a query by BLASTp for homology search. The potential templates were then aligned using Clustal Omega webserver (http://www.ebi.ac.uk/Tools/msa/clustalo/) and secondary structure predictions were done using ESPRIPT Cloning, overexpression, and purification of recombinant SlugATIC S. lugdunensis purH gene encoding the SlugATIC (5-492), a protein of 492 amino acids, was amplified by PCR from genomic DNA of S. lugdunensis using gene-specific primers SlugATIC-F/SlugATIC-R (Table S5 ). The amplified PCR product was cloned into the expression vector pET-21a, and the resulting recombinant was termed as pET-21a-SlugA-TIC. The recombinant plasmid pET-21a-SlugATIC was transformed into freshly prepared E. coli BL-21 (DE3) cells for the overexpression of recombinant untagged SlugATIC protein. The SlugATIC overexpression was induced with 200 lM IPTG when the OD 600 value reached 0.6-0.7. The culture after induction was transferred to 18°C and grown for~16 h. Cells were harvested by centrifugation at 3000 g for 10 min at 4°C, and the cell pellets were stored in À80°C until use. The purification procedure was carried Fig. 20 . Schematic representation elucidating the probable scheme for the mode of action of SlugATIC-induced cell proliferation in NIH 3T3 fibroblasts cells and pancreatic RIN-5F beta cells. SlugATIC enzyme helps in the in vitro wound healing of NIH 3T3 fibroblasts and also helps in rescuing the pancreatic beta cell from cytotoxic effects of palmitic acid and high glucose. SlugATIC enzyme efficiently metabolizes its substrate AICAR to IMP in the last two steps of de novo purine biosynthesis pathway. Thus, SlugATIC manifests its role as a cell proliferation agent due to the consumption of AICAR as well as the production of new nucleotide, i.e., IMP. Deviations in the level of ATIC gene in the cell or inhibition by drugs like Pemetrexed lead to accumulation of AICAR which acts as an activator of AMPK. AMPK is a sensor for cellular energy and is responsible for cell growth, proliferation, and apoptosis. On activation by AICAR, AMPK inhibits mTOR pathway and also decreases the cell cyclins level leading to inhibition of the cell proliferation and promotion of cell cycle arrest. AMPK, adenosine monophosphate-activated protein kinase; mTOR, mammalian target of rapamycin. out at 4°C. For purification of untagged SlugATIC protein, the recombinant pET-21a-SlugATIC frozen cell pellets were resuspended in binding buffer A [50 mM NaH 2 PO 4 , pH 7.4, 20 mM NaCl, 5% glycerol, 1 mM EDTA containing lysozyme (0.5 mgÁmL À1 ), 0.3 mM phenylmethylsulfonyl chloride and protease inhibitor cocktail] and lysed by sonication. Cellular debris was removed by centrifugation at 28 000 g for 1 h. The clarified supernatant was loaded onto CM-sepharose column (1.5 9 20 cm, Econo-column; BioRad, Richmond, CA, USA) pre-equilibrated with binding buffer A. The flow through (FT) of CM-sepharose was collected and loaded onto a pre-equilibrated DEAE-sepharose column (1.5 9 20 cm, Econo-column; Bio-Rad). The unbound proteins were washed away with binding buffer, and the bound proteins were eluted in the same buffer with a NaCl step gradient from 0 to 0.5 M. Fractions were assayed for AICAR TFase and IMPCHase activity and peak activity fractions were pooled and diluted with buffer B (20 mM Tris/HCl, pH 7.4, 2.5 M NaCl, 5% glycerol, and 1 mM EDTA). The active protein was concentrated using Amicon Ultra concentrator with 10 kDa cut off (Millipore, Bedford, MA, USA) and buffer exchanged in buffer B and subsequently concentrated to a final volume of 8-10 mL.
The dialyzed protein was further purified using hydrophobic interaction chromatography (HIC) and loaded onto octyl sepharose 4 fast flow (GE Healthcare, Uppsala, Sweden) column pre-equilibrated with the buffer B. The unbound proteins were removed by washing with the buffer B and eluted with a multi-step gradient of NaCl from 2 M to 0.1 M, in 20 mM Tris/HCl (pH 7.4), 5% glycerol and 1 mM EDTA. The active fractions were further pooled, concentrated, and loaded onto HiLoad 16/600 Superdex 200 pg gel-filtration column for further purity. The running buffer used for size exclusion chromatography was buffer C (20 mM Tris/HCl, pH 7.4, 150 mM NaCl, 50 mM KCl, 5 mM EDTA, and 5 mM DTT). Fractions of the major peak containing pure protein were pooled and concentrated. The protein fractions and the purified protein throughout the purification were analyzed on 12% SDS/PAGE.
Construction of domain truncation mutants
Variable portions of SlugATIC gene were amplified by PCR from genomic DNA of S. lugdunensis in order to recognize the probable functional activity domains. Three truncation mutants were built, an N-terminal truncation mutant encoding the first 200 amino acids of ATIC and two carboxyterminal truncation mutants expressing the last 314 and 302 amino acids. The N-terminal truncation mutant, IMPCH, was generated by the amplification of first 600 nucleotides (1-600) of purH gene using primers IMPCH-F/IMPCH-R (Table S5 ). The first C-terminal truncation mutant, AICARTF 1 , was constructed by the amplification of nucleotide 568-1476, and second truncation mutant, AICARTF 2 , was built via amplification of 532-1476 nucleotide using primers AICARTF 1 -F/SlugATIC-R and AICARTF 2 -F/SlugATIC-R, respectively (Table S5 ). The amplified products were ligated into double restriction digested pET-28c(+) vector, and correct construction frames of the three constructs were confirmed by DNA sequencing. The resultant recombinant plasmids were named as pET-28c-IMPCH, pET-28c-AICARTF 1 , and pET-28c-AICARTF 2 , respectively.
Overexpression and purification of truncation mutants
The positive clones encoding the truncation mutants were transformed into Rosetta cells for the expression of the recombinant IMPCH and AICARTF 1 and AICARTF 2 domains, respectively. The N-terminal histidine-tagged IMPCH and AICARTF 1 and AICARTF 2 were purified to homogeneity using Ni
2+
-NTA affinity chromatography. Purified proteins were subjected to TEV protease cleavage followed by reverse affinity chromatography to purify the His-tag cleaved protein.
Purified proteins were dialyzed against buffer C for future use.
Enzyme assays and kinetic analysis
For AICAR Transformylase activity (AICAR TFase) assay, the reaction was performed according to the methodology of Mueller and Benkovic [12] . AICAR TFase assay mixture consisted of 66 mM Tris/HCl (pH 7.4), 50 mM KCl, 5 mM bME, 0.1 mM 10-f-THF, and SlugATIC enzyme in a final reaction volume of 500 lL. The assay solution was mixed before the addition of AICAR (0.05 mM) and subsequently mixed again. The AICAR TFase activity was measured by the absorbance increase at 298 nm corresponding to the formation of THF as described by Black et al. [42] . AICAR TFase enzyme activity was checked similarly in the IMPCH, AICARTF 1 , and AICARTF 2 truncation mutants. 10-f-THF was kindly provided by Merck and Cie (Schaffhausen, Switzerland), and AICAR monophosphate was purchased from Sigma.
For Inosine monophosphate cyclohydrolase (IMPCHase) assay, the reaction mixture contained final concentration of 100 mM Tris/HCl (pH 7.4) and 0.1 mM FAICAR. After mixing, SlugATIC enzyme was added to a total reaction volume of 500 lL. The IMPCHase activity was estimated by the production of IMP as an increase in absorbance at 248 nm [12] . IMPCHase activity was also checked for IMPCH, AICARTF 1 , and AICARTF 2 truncation mutants. FAICAR was a kind gift from Dr Ian Wilson laboratory (Scripps Research Institute, La Jolla, CA, USA).
Steady-state kinetic analysis
The standard AICAR TFase and IMPCHase assay was used for determining the steady-state kinetic parameters for the SlugATIC as well as the IMPCH and AICARTF 1 truncation mutant. In AICAR TFase assay, the experiments were designed by varying the concentrations of both AICAR and 10-f-THF. In IMPCHase assay, varying concentrations of FAICAR were plotted against the velocity. The enzyme kinetics data were fitted to the Michaelis-Menten equation by using nonlinear regression (GraphPad Prism) to determine the K m and V max of substrate conversion.
Characterization of SlugATIC
SlugATIC was assayed in different buffers (pH range [5] [6] [7] [8] [9] [10] to determine the optimum pH for its AICAR TFase enzyme activity using 10-f-THF and AICAR as substrates. Likewise, the optimum pH for IMPCHase activity of SlugATIC was determined at room temperature using FAI-CAR as substrate. Additionally, the pH stability of SlugATIC for AICAR TFase and IMPCHase enzyme activity was also measured by incubating the reaction mixtures without substrates for 1 h with the buffers ranging in pH from 5 to 10. The residual AICAR TFase and IMPCHase enzyme activity was determined afterward using their respective substrates as mentioned above.
The effect of temperature on AICAR TFase and IMPCHase activities of SlugATIC was also assessed by incubating the reaction mixtures excluding substrates for 10 min at different temperatures ranging from 10 to 60°C. Subsequently after heat treatment, the residual activity (AICAR TFase and IMPCHase) of the SlugATIC enzyme was assayed by standard procedures. For determining the thermostability of SlugATIC, purified enzyme in Tris/HCl buffer was incubated at different temperatures (10-60°C) for 30 min and the residual enzyme activity was measured using the standard assay procedures as mentioned above. The experiments presented above were performed in triplicate.
Construction of SlugATIC mutants
Site-directed mutagenesis was performed on pET-21a-SlugA-TIC plasmid using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) as per the manufacturer instructions. Mutations and the respective synthetic mutagenic oligonucleotide primers designed are mentioned in Table S6 . The amplified product was subjected to DpnI digestion at 37°C for 1 h and subsequently transformed into XL-1 Blue competent cells. The positive mutant plasmids were used to express the corresponding mutant proteins which were purified and assayed for AICAR TFase activity as mentioned above for the wild-type SlugATIC enzyme.
Characterization of oligomerization state
Protein cross-linking
Glutaraldehyde cross-linking studies were done in order to obtain the preliminary knowledge about the quaternary structure of SlugATIC. For cross-linking experiment, the purified protein was exchanged in 20 mM sodium phosphate buffer (pH 7.5). The reaction was started by incubating 15 lL of SlugATIC (1 mgÁmL À1 ) for 10 min at 37°C with varying final concentrations of acidified glutaraldehyde ranging from 0 to 0.06% (v/v). The reaction was terminated by heating the sample with SDS/PAGE loading buffer, and cross-linked oligomers were analyzed on 12% SDS/PAGE.
Oligomeric state determination
For oligomeric state analysis, purified protein was concentrated and loaded onto HiLoad 16/600 Superdex 200 pg gel-filtration column equilibrated with buffer C. Protein elution profile was examined by measuring the absorbance at 280 nm. Approximate molecular mass of SlugATIC was calculated using the standard curve derived from the Bio-Rad gel-filtration standards. Similarly, the oligomeric state of IMPCH and AICARTF 1 truncation mutant was also determined using their purified and concentrated protein.
Effect of NaCl and urea on SlugATIC oligomeric state
To investigate the effect of NaCl and urea on SlugATIC oligomeric state, purified and concentrated protein was preincubated with varying concentration (2 M or 4 M) of the above-mentioned chemical reagents individually for 6 h at 4°C. The protein was further applied onto a Hi-Load 16/ 600 Superdex 200 gel-filtration column pre-equilibrated with buffer C including the same concentration of NaCl or urea and the elution profiles were inferred.
Differential scanning calorimetry
Differential scanning calorimetric measurements were carried over a temperature range of 10-90°C at a scan rate of 1.0°CÁmin À1 using Microcal VP-DSC Microcalorimeter (Microcal, Northampton, MA, USA). For studying protein thermal unfolding of IMPCH, AICARTF 1 , SlugATIC, and IMPCH/AICARTF 1 proteins in solution, all protein samples (0.12 mM) were extensively buffer exchanged against phosphate-buffered saline (20 mM phosphate buffer pH 7.4, containing 100 mM NaCl and 150 mM KCl) or phosphate buffer (20 mM phosphate buffer, pH 7.4) with Spectra Por Dialysis Membrane (molecular weight cut off 10 000 Da) (Spectrum Laboratories, Laguna Hills, CA, USA). The resultant dialysate buffer was used as reference cell solution for accuracy and repetition. Prior to loading, all solutions were filtered using 0.22-lm pore size membrane filter, followed by degassing with MicroCal Thermovac2 (GE Healthcare, MicroCal, Northampton, MA, USA) degasser. Each DSC data were analyzed using ORIGIN 7 software (OriginLab Corp., Northampton, MA, USA) and further processed by fitting according to a non-2-state model. Likewise, the effect of mutations on the thermostability of SlugATIC protein was also studied using DSC experiments. For ligand-binding thermal studies, DSC thermograms were recorded for SlugATIC + 1.5-2.5 mM 5-f-THF, SlugATIC + 1-2 mM AICAR and SlugATIC + 5-f-THF (2.5 mM) + AICAR (1-2 mM) . Similarly, AICARTF 1 DSC thermograms were collected individually with 0.5-2.0 mM 5-f-THF and 1-2 mM AICAR and in combination (2.0 mM 5-f-THF and 1 mM AICAR). We have used 5-f-THF (Merck and Cie) in place of 10-f-THF for studying the effect of folate binding on SlugATIC. The protein concentration of SlugATIC was adjusted to 0.05 mM with the help of dialysis buffer, while 0.12 mM was used for AICARTF 1 protein for these DSC experiments.
Cell culture NIH 3T3 mouse embryonic fibroblast cell line and RIN-5F rat clonal pancreatic beta-cell line were acquired from National Centre for Cell Science (NCCS), Pune, India. Mouse NIH 3T3 cells were grown in Dulbecco's modified Eagle's media (DMEM), while rat RIN-5F cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco, BRL, Inchinnan, UK) and 1% antibiotic mix (100 UÁmL À1 penicillin and 100 lgÁmL À1 streptomycin) (HiMedia, Mumbai, India) and maintained in a humidified CO 2 incubator at 37°C.
Cell proliferation assay
The proliferation effect of SlugATIC was determined on different cell lines, NIH 3T3 and RIN-5F by MTT assay. In brief, cells were seeded at a density of 5 9 10 3 cells/well in a 96-well microtiter plate (Greiner, Germany). After 24 h of seeding, varying concentrations of SlugATIC protein (0.1, 1, 5, 10, 15, 20, 25, and 50 lM) in PBS (phosphate-buffered saline) was added to the monolayer of NIH 3T3 cells and then incubated at 37°C for 12 and 24 h. Similarly, RIN-5F cells were also exposed to SlugATIC at a concentration of 0.1, 1, 5, 10, 15 lM for 48 h. The buffer without protein was used as vehicle control. After the respective treatment, the cells were assayed by addition of 20 lL of MTT (5 mgÁmL
À1
) solution for 4 h at 37°C. The MTT-containing medium was further aspirated and 200 lL of DMSO was added to dissolve the formazan crystals. The optical density was measured at 570 nm by ELISA plate reader (Fluostar Optima; BMG Labtech GmbH, Offenburg, Germany). Experiments were performed in triplicates and the results were expressed as percentage cell viability.
Further to investigate the independent effect of AICAR or IMP on both the cells, cells were treated with different concentrations of AICAR or IMP and incubated for 24 h in case of NIH 3T3 cells and 48 h for RIN-5F cells. Based on the pre-existing literature studies, varying concentrations of AICAR (10 lM to 1 mM) and IMP (10-200 lM) were chosen for present studies [35, 43] . On completion of incubation, MTT assay was performed as described above. Further based on these results, out of various doses, two significant doses of AICAR and IMP were chosen for both the cell lines. Subsequently, cells were co-treated with indicated concentrations of SlugATIC protein and the AICAR or IMP for 24 and 48 h in NIH 3T3 and RIN-5F cells, respectively. After the treatment, MTT assay was carried out. Further, for the tests of time-dependent effects of AICAR or IMP on both the cell lines, cells were treated with AICAR or IMP along with SlugATIC protein for various time period and MTT assay was performed. The concentration of SlugATIC protein used in this set of experiment is 25 lM for NIH 3T3 cells and 5 lM for RIN-5F cells based on the proliferation results by previous MTT experiments.
Determination of lipotoxicity and glucotoxicity in RIN-5F cells
To determine palmitic acid (PA)-induced cytotoxicity in RIN-5F cells, RIN-5F cells were cultured in presence or absence of 0.5 mM PA containing medium. Similarly, the toxicity of high glucose (HG) on pancreatic beta cells was determined by growing the RIN-5F cells in medium containing two different concentrations of glucose, that is, 5.5 and 25 mM. In both the cases, the cytotoxicity was measured for different time duration.
Further, the PA (0.5 mM) and HG (25 mM) treated RIN-5F cells were incubated with varying concentrations of SlugATIC to study the protective effect of SlugATIC from induced lipotoxicity and glucotoxicity in pancreatic RIN-5F beta cells. The doses chosen were similar as used in MTT assay for RIN-5F cells in normal condition (0.1, 1, 5, 10, 15 lM). In brief, the RIN-5F cells incubated in PA/HG medium were treated with SlugATIC for 48 h and the cultures were analyzed for cytotoxicity by MTT assay as described above. Untreated cells grown in medium containing PA/HG served as control and were used in comparison for SlugATIC-treated cells.
DAPI staining
In order to study the proliferation effect of SlugATIC on NIH 3T3 cells and anti-apoptotic and cell proliferative activity on RIN-5F cells, the treated cells were stained with DAPI and examined by fluorescence microscopy. Briefly, 
In vitro wound-healing (scratch) assay
In order to examine the cellular proliferation effect of SlugATIC, wound-healing assay was performed as described by Yi et al. [44] . In brief, NIH 3T3 and RIN-5F cells were seeded in a six-well plate and cultured until 90% confluent. The media was then removed and equal size 'wound' was simulated using a 200 lL sterile pipette tip. This was followed by rinsing the cells with PBS to remove dislodged cells. Further, NIH 3T3 cells were treated with 25 lM SlugATIC for 12 and 24 h, while RIN-5F cells were treated with 5 lM of SlugATIC for 48 h. The media without SlugATIC protein was added to the control group for similar time duration. After treatment, cellular proliferation over the scratched area was monitored and the images were acquired by phase contrast inverted microscope (Axiovert 25; Zeiss) under 509 magnification and evaluated using IM-AGE-J software (NIH, Bethesda, MD, USA). The migration of cells was evaluated by calculating the width of the monolayer wounds and results were expressed as the percentage of control. Similar to the MTT assay, to check the independent effect of AICAR or IMP alone and their effect along with protein, cells were treated with respective treatments as described in MTT assay and scratch assay was carried out as described above.
Statistical analysis
GRAPHPAD PRISM 5.01 software (GraphPad Software, San Diego, CA, USA) was used for statistical analysis and the data are expressed as mean AE SEM. For statistical evaluation of data, one-way ANOVA followed by the Bonferroni post hoc test was used and a P-value of < 0.05 was considered to be statistically significant.
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